Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
159,231,812
-
Total 13F shares
-
115,545,961
-
Share change
-
-1,210,183
-
Total reported value
-
$696,530,447
-
Put/Call ratio
-
26%
-
Price per share
-
$6.03
-
Number of holders
-
217
-
Value change
-
-$6,968,225
-
Number of buys
-
87
-
Number of sells
-
107
Institutional Holders of Vir Biotechnology, Inc. - Common Stock, $0.0001 par value (VIR) as of Q4 2025
As of 31 Dec 2025,
Vir Biotechnology, Inc. - Common Stock, $0.0001 par value (VIR) was held by
217 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
115,545,961 shares.
The largest 10 holders included
BlackRock, Inc., SB INVESTMENT ADVISERS (UK) LTD, ARCH Venture Management, LLC, VANGUARD GROUP INC, GSK plc, STATE STREET CORP, FMR LLC, MORGAN STANLEY, DIMENSIONAL FUND ADVISORS LP, and ORBIMED ADVISORS LLC.
This page lists
217
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.